Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
MCS110 + BRAF/MEK Inhibitors for Melanoma
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a combination of two targeted therapies, MCS110 and Dabrafenib, as a possible treatment for advanced melanoma patients with a BRAF V600E or BRAF V600K genetic mutation.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.